Creative Biolabs stands as a prominent authority proficient in harnessing hybridoma technology for the advancement of monoclonal antibody (mAb) development. Leveraging our wealth of expertise and cutting-edge framework, we take pride in extending hybridoma solutions across various species to cater to a global clientele.

Introduction of Hybridoma Services

Hybridoma technology, a time-honored approach for the sustained production of mAb on a large scale, involves the fusion of specific antibody-producing B lymphoblasts with myeloma cells, culminating in the generation of hybrid cell lines pivotal to this technique. The process typically commences with animal immunization, followed by the isolation of splenocytes, from which B cells generating target-specific antibodies are extracted and subsequently fused with myeloma cells. These resultant stable hybridoma cells exhibit the capacity for continuous expression of antigen-specific mAbs. These mAbs hold significant value not only in fundamental research within the realms of biology and immunology but also in diverse medical contexts. Furthermore, bolstered by supplementary advanced methodologies offered at Creative Biolabs, such as hybridoma sequencing, anti-idiotype Antibody production, and antibody-drug conjugates (ADCs), the expanded utilization of mAbs can significantly contribute to the development of therapeutic or diagnostic modalities.

Fig.1 Hybridoma technology.

One-Stop MAb Production via Hybridoma Technology

Custom Antibody & Hybridoma Services

Characteristics of Hybridoma Services

• Exceptional specificity, affinity, and precision;
• A wide array of species options;
• Capability to discern nuanced alterations (such as post-translational modifications);
• Production of extensive arrays of functional antibodies;
• Access to thorough functional assessments;
• Identification of novel epitopes;
• Superior immunohistochemistry outcomes with formalin-fixed paraffin-embedded specimens;
• Remarkable outcomes for challenging antigens;
• Availability of high-throughput screening infrastructure;

Related Applications

Fig.2 Application of hybridoma services.

• Medical Diagnostics: Precision Instrumentation for Disease Detection

The advent of hybridoma technology has transformed medical diagnostics, furnishing exceptionally precise mAb tailored for diverse assays. Employed in methodologies like ELISA, immunofluorescence, and Western blotting, these antibodies facilitate the identification of targeted proteins or pathogens within clinical specimens. This level of precision is crucial for facilitating early and accurate disease detection.

• Therapeutics: Precision Pharmacotherapy Enabled by MAb

MAbs synthesized via hybridoma technology have emerged as indispensable components of therapeutic modalities. Whether addressing breast cancer or lymphoma, these antibodies are meticulously engineered to selectively target disease-associated molecules. The outcome is a therapeutic strategy characterized by minimized adverse effects and optimized efficacy.

• Foundational Investigation: Shedding Light on Cellular Enigmas

Hybridoma technology has propelled fundamental inquiries in immunological, cellular, and associated disciplines. MAbs, serving as indispensable instruments, expedite the examination of distinct proteins, thereby elucidating cellular phenomena and unraveling the molecular intricacies inherent to diverse diseases.

Case Study

• Peptide Immunogen Design and Hybridoma Development

The client provided a protein target X, we designed a peptide immunogen and did the function test of selected positive hybridoma. Fig.2 is the ELISA titration result in the immunization process. Fig.3 is the ELISA result of the finally selected hybridomas.

• Antibody Pair Development

As an industrial leader specializing in custom services, Creative Biolabs also provides gene-engineered antibodies including single-domain antibodies and humanized antibodies. Moreover, we can conduct phage display antibody library screening and antibody development by the single B cell sorting platform. Should you express interest in our offerings, we warmly encourage you to reach out for further elucidation.

Resources

Use the resources in our library to help you understand your options and make critical decisions for your study.

FAQ

1. Q: What level of customization is available in your antibody development services?

   A: We offer a full suite of services, beginning with meticulous antigen preparation and extending through tailored immunization strategies, hybridoma generation, comprehensive screening, and efficient antibody production and purification. This end-to-end customization ensures that the final antibody product is precisely matched to the client's specific application needs. Clients can expect close collaboration and consultation throughout the process, guaranteeing a successful outcome.

2. Q: What are the specific requirements for the antigen I provide, and can you assist with antigen design?

   A: We can work with various antigen types, including peptides, proteins, whole cells, or even DNA. Our scientific team offers comprehensive antigen design consultation and, if required, can undertake full antigen production, including synthesis and conjugation, ensuring optimal immunogenicity for your project.

3. Q: How do you guarantee the quality and specificity of the developed antibodies?

   A: We employ rigorous quality control measures at every stage. The hybridoma technology itself contributes to high specificity by nature. In addition, we utilize advanced screening techniques to identify and select hybridomas that produce antibodies with the desired characteristics. These screening processes often involve multiple assays to validate specificity, affinity, and functionality, ensuring that only the highest quality antibodies are delivered to the client.

4. Q: How do you help clients decide which host species is most appropriate for their specific antigen and downstream applications?

   A: The choice of host species can significantly impact antibody performance. Our experts will discuss your specific research goals, the nature of your antigen (especially its homology to host species proteins), and intended applications to recommend the optimal species—be it mouse, rat, rabbit, or others—to maximize the likelihood of a robust immune response and functional antibody generation.

5. Q: What kind of success rates do you observe, particularly for developing antibodies against challenging targets like membrane proteins or those requiring recognition of specific post-translational modifications?

   A: While success can never be absolutely guaranteed in biological research, our extensive experience and diverse technological platforms, including specialized membrane protein antibody development strategies and meticulous screening, allow us to achieve high success rates, even for notoriously difficult antigens or those needing to detect subtle modifications.

6. Q: What is the typical timeline for developing a custom monoclonal antibody, from project initiation to final antibody delivery?

   A: A standard monoclonal antibody development project using hybridoma technology generally spans several months, typically ranging from 4 to 6 months. However, this can vary based on factors like antigen complexity, the species chosen, and the specific screening assays required for your target.

7. Q: What kind of post-delivery assistance can I expect if I encounter issues when using the custom antibody in my experiments?

   A: Researchers may occasionally face challenges integrating a new antibody into their assays. We provide post-delivery technical support to help troubleshoot any issues you might encounter. Our scientific team can offer guidance on optimal antibody handling, storage, and application-specific protocols to help you achieve the best results.

8. Q: Who owns the intellectual property (IP) for the custom antibodies and cell lines developed through your service?

   A: Clarity on intellectual property rights is essential for commercial and academic endeavors. For fee-for-service projects, the client typically retains full ownership of the developed antibodies and any associated cell lines. We ensure this is clearly outlined in our service agreements, providing you with the freedom to use and commercialize the results of your project.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.